IIF Shonan Health Innovation Park
information
F-22
- Location
- 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, Japan
- Acquisition Price (mn Yen)
- 38,500
- Date Acquired
-
Sep. 30, 2020
Aug. 02, 2021 - Construction Completion
- Feb. 15, 2011
- Number of Stories
- Main building: 9-story steel frame roof *1
- Land Size
- 220,356.28 m2
- Zoning
- Industrial area / Industrial-only area
- Total Floor Space
- 298,435.64 m2
- Number of Tenants
- 7
- Occupancy Ratio
- 99.2％
- Major Tenant
- Takeda Pharmaceutical Company Limited
*1 Number of stories is described main building.
*2 IIF acquired 60% co-ownership interest of the trust beneficiary right in real estate of this property on September 30, 2020 (acquisition price: 23,100 million yen) and the remaining 40% co-ownership interest on August 2, 2021 (acquisition price: 15,400 million yen).
IIF acquired a Life Science Park equipped with one of the largest research facilities in Japan, through a CRE propose to Takeda Pharmaceutical Company Limited (“Takeda”). Institutions from industry-government-academia fields, drug discovery companies and next-generation medical companies also use this property as a facility that aims to industrialize in the cutting-edge medical field to be expected to expand the market in the future.
A new company, “iPark Institute Co., Ltd.(“iPi”) was established as the management company, and IIF acquired shares in iPi (shareholding ratio of 41.0%) with the aim of planning to further develop the facility with the mission of "Establish a life science ecosystem open to the world", strengthen the operational structure (business and innovation creation, operational management, and participation in urban development), plan collaboration with over 150 companies in the pharmaceutical, next-generation medical, and startup industries, etc., and secure highly experienced personnel with advanced knowledge of life science parks management.
As a result, the management structure will be shifted from the current management structure managed by Takeda to a new management structure managed by iPi, whose major shareholders are IIF, Takeda, and Mitsubishi Corporation.
Furthermore, through this initiative, the collaboration with Takeda and Mitsubishi Corporation, which has been involved since November 2019 in the property as part of its membership, and has actively studied and explored various measures to promote engagement with business in the healthcare, drug discovery support, and biological related businesses, and engaged in complex urban development activities as part of the redevelopment plan for the surrounding area, will be further strengthened, which is expected to enhance the efficiency of the management, support start-ups, and collaborate with the local community, and further enhance the property's scarcity and asset value, as well as contribute to the profitability and stability of the property. Moreover, KJR Management, the asset manager, dispatches a director with expertise in real estate management to iPi. By strengthening governance and integrating the global expertise of the sponsor, KKR Group, the further contributions to the development of the Life Science Park is expected.
For the details of iPi, please refer to the website.
Income
Please refer to "Performance by Property (xls)"
Map
F-22
IIF Shonan Health Innovation Park
- Location
- 26-1, Muraoka-Higashi 2-chome, Fujisawa-shi, Kanagawa, Japan
- Acquisition Price (mn Yen)
- 38,500
- Date Acquired
-
Sep. 30, 2020
Aug. 02, 2021 - Construction Completion
- Feb. 15, 2011
- Number of Stories
- Main building: 9-story steel frame roof *1
- Land Size
- 220,356.28 m2
- Zoning
- Industrial area / Industrial-only area
- Total Floor Space
- 298,435.64 m2
- Number of Tenants
- 7
- Occupancy Ratio
- 99.2％
- Major Tenant
- Takeda Pharmaceutical Company Limited
*1 Number of stories is described main building.
*2 IIF acquired 60% co-ownership interest of the trust beneficiary right in real estate of this property on September 30, 2020 (acquisition price: 23,100 million yen) and the remaining 40% co-ownership interest on August 2, 2021 (acquisition price: 15,400 million yen).